PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Annals of Oncology10.1093/annonc/mdw378.31201627vi369A meta-analysis of immune-related adverse events (irAE) of immune checkpoint inhibitors (ICI) from cancer clinical trialsB. El Osta, F. Hu, R. Sadek, R. Chintalapally, S.-C. Tanghttps://api.elsevier.com/content/article/PII:S0923753419447029?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419447029?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/27/suppl_6/1077P/19451202/mdw378.31.pdf
Cancer Research and Treatment10.4143/crt.2020.7902021532339-354The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 PatientsSi-Qi Tang, Ling-Long Tang, Yan-Ping Mao, Wen-Fei Li, Lei Chen, Yuan Zhang, Ying Guo, Qing Liu, Ying Sun, Cheng Xu, Jun Mahttp://e-crt.org/upload/pdf/crt-2020-790.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2020.790, http://e-crt.org/upload/pdf/crt-2020-790.pdf
Frontiers in Pharmacology10.3389/fphar.2021.686876202112Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical TrialsWeidong Zhang, Jingjing Gu, Chunming Bian, Guanhong Huanghttps://www.frontiersin.org/articles/10.3389/fphar.2021.686876/full
BMC Cancer10.1186/s12885-020-07518-52020201The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitorsZahra Karimian, Sandra Mavoungou, Joe-Elie Salem, Florence Tubach, Agn├Ęs Dechartreshttp://link.springer.com/content/pdf/10.1186/s12885-020-07518-5.pdf, http://link.springer.com/article/10.1186/s12885-020-07518-5/fulltext.html, http://link.springer.com/content/pdf/10.1186/s12885-020-07518-5.pdf
Immune Network10.4110/in.2020.20.e92020201Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint InhibitorsJuwhan Choi, Sung Yong Leehttps://synapse.koreamed.org/pdf/10.4110/in.2020.20.e9, https://synapse.koreamed.org/DOIx.php?id=10.4110/in.2020.20.e9, https://immunenetwork.org/DOIx.php?id=10.4110/in.2020.20.e9
Allergology International10.1016/j.alit.2022.01.0012022712169-178Immune-related adverse events in various organs caused by immune checkpoint inhibitorsNaoko Okiyama, Ryota Tanakahttps://api.elsevier.com/content/article/PII:S1323893022000028?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1323893022000028?httpAccept=text/plain
Cancers10.3390/cancers140307922022143792Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal DiseasesYoshiaki Yura, Masakazu Hamadahttps://www.mdpi.com/2072-6694/14/3/792/pdf
Clinical Infectious Diseases10.1093/cid/ciz51220197071519-1519Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint InhibitorsGeert H Groeneveld, Dirk H Wijn, Albert M Vollaardhttp://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciz512/28836878/ciz512.pdf, http://academic.oup.com/cid/article-pdf/70/7/1519/32921237/ciz512.pdf, http://academic.oup.com/cid/article-pdf/70/7/1519/32921237/ciz512.pdf
10.21203/rs.3.rs-44819/v22020The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitorsZahra Karimian, Sandra Mavoungou, Joe-Elie Salem, Florence Tubach, Agnes Dechartreshttps://www.researchsquare.com/article/rs-44819/v2, https://www.researchsquare.com/article/rs-44819/v2.html
10.21203/rs.3.rs-44819/v32020The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitorsZahra Karimian, Sandra Mavoungou, Joe-Elie Salem, Florence Tubach, Agnes Dechartreshttps://www.researchsquare.com/article/rs-44819/v3, https://www.researchsquare.com/article/rs-44819/v3.html